{"title": "Novartis lays out $650M-plus for BeiGene's tislelizumab as its own PD-1 fails to impress", "author": "Angus Liu", "url": "https://www.fiercepharma.com/marketing/novartis-takes-celgene-s-baton-licensing-beigene-s-tislelizumab-as-own-pd-1-fails-to", "hostname": "fiercepharma.com", "description": "Novartis is way late to the PD-1/L1 game, and, after its own project flunked a late-stage study, the Swiss pharma figures it needs an external candidate as belt and braces. | Novartis is way late to the PD-1/L1 game, and, after its own project flunked a late-stage study, the Swiss pharma figures it needs an external candidate as belt and braces. So it picked BeiGene's PD-1 inhibitor tislelizumab, previously partnered with cancer heavyweight Celgene until its merger with Opdivo developer Bristol Myers Squibb.", "sitename": "FiercePharma", "date": "2021-01-12", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}